First Time Loading...

Thalys Medical Technology Group Inc
SSE:603716

Watchlist Manager
Thalys Medical Technology Group Inc Logo
Thalys Medical Technology Group Inc
SSE:603716
Watchlist
Price: 7.57 CNY 0.93% Market Closed
Updated: May 7, 2024
Section:
 

Relative Value

The Relative Value of one Thalys Medical Technology Group Inc stock under the Base Case scenario is 25.7 CNY. Compared to the current market price of 7.57 CNY, Thalys Medical Technology Group Inc is Undervalued by 71%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
25.7 CNY
Undervaluation 71%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.7
P/S
P/S
Price to Sales
0.7
vs History
96
vs Industry
90
Median 3Y
1
Median 5Y
1.1
Industry
8.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-14.5
Median 5Y
30.7
Industry
26.8
More Details
46
P/OCF
P/OCF
Price to OCF
46
vs History
34
vs Industry
4
Median 3Y
37
Median 5Y
30.2
Industry
23.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
7
Median 3Y
-9.5
Median 5Y
-7.9
Industry
21.4
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
96
vs Industry
61
Median 3Y
1.6
Median 5Y
1.8
Industry
2.6
More Details
1.2
EV/S
EV/S
Enterprise Value to Sales
1.2
vs History
96
vs Industry
76
Median 3Y
1.4
Median 5Y
1.5
Industry
7.5
More Details
6.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.6
vs History
88
vs Industry
51
Median 3Y
7
Median 5Y
7.3
Industry
9.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
17.2
Median 5Y
18.6
Industry
4.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
17.2
Median 5Y
18.6
Industry
4.4
More Details
72.9
EV/OCF
EV/OCF
Enterprise Value to OCF
72.9
vs History
33
vs Industry
2
Median 3Y
47.6
Median 5Y
34.7
Industry
5.6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
7
Median 3Y
-29.5
Median 5Y
-29.5
Industry
3.4
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
96
vs Industry
61
Median 3Y
1.2
Median 5Y
1.2
Industry
5
More Details

Multiples Across Competitors

Competitors Multiples
Thalys Medical Technology Group Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Thalys Medical Technology Group Inc
SSE:603716
1.5B CNY 0.7 -10.1 -29.1 -29.1
US
Abbvie Inc
NYSE:ABBV
287.4B USD 5.3 59.6 12.9 19.7
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 5.4 42.7 18.2 29.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
105.6B USD 8.1 27.4 22.1 24.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.7B USD 10.5 28.7 22.9 24
AU
CSL Ltd
ASX:CSL
133.1B AUD 6.2 35.7 21.6 26.8
US
Gilead Sciences Inc
NASDAQ:GILD
81.7B USD 3 168.7 6.8 8.9
US
Moderna Inc
NASDAQ:MRNA
46.8B USD 9.1 -7.8 -8.5 -7.6
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
32.2B USD 3.3 27.6 14.1 17.7
KR
Celltrion Inc
KRX:068270
40.2T KRW 18.5 75.1 45.9 63.2
EV/EBITDA Multiple
EBITDA Growth
CN
Thalys Medical Technology Group Inc
SSE:603716
Average EV/EBITDA: 20.6
Negative Multiple: -29.1 		N/A
US
Abbvie Inc
NYSE:ABBV
12.9
26%
US
Amgen Inc
NASDAQ:AMGN
18.2
62%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
22.1
50%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
59%
AU
CSL Ltd
ASX:CSL
21.6
54%
US
Gilead Sciences Inc
NASDAQ:GILD
6.8
18%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -8.5 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Biogen Inc
NASDAQ:BIIB
14.1
67%
KR
Celltrion Inc
KRX:068270
45.9
109%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.